Clinical trial NCT00390156 (phase 1, status: completed)
Conditions: unspecified adult solid tumor
ICD codes: H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: cyclophosphamide, imatinib
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of solid tumor

               -  Advanced or metastatic disease* NOTE: *With the exception of colorectal and lung
                  cancer patients, all patients must receive approval from the insurance carrier
                  that allows for coverage/payment of the study drug bevacizumab

          -  Refractory to standard therapy OR no standard therapy exists

          -  No advanced ovarian cancer or peritoneal carcinomatosis

          -  No metastases from any cancer causing significant ascites

          -  No lung malignancy with any of the following characteristics:

               -  In close proximity to a major vessel

               -  Centrally located

               -  Cavitary

               -  Squamous histology

               -  Hemoptysis > ½ teaspoon per day

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Platelet count ≥ 100,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Bilirubin < 2 mg/dL

          -  AST or ALT < 3 times upper limit of normal

          -  Creatinine < 2 mg/dL

          -  Urine protein:creatinine ratio ≤ 1.0

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Able to tolerate oral therapy

          -  No bleeding diatheses or coagulopathy

          -  No impairment of gastrointestinal (GI) function or GI disease that may affect or alter
             absorption of imatinib mesylate and/or cyclophosphamide (e.g., malabsorption syndrome,
             history of total gastrectomy/significant small bowel resection)

          -  No abdominal fistula, GI perforation, or intra-abdominal abscess within the past 6
             months

          -  No uncontrolled hypertension (i.e., blood pressure > 150/100 mm Hg)

          -  No uncontrolled cardiovascular disease, including any of the following:

               -  Coronary artery disease

               -  Uncontrolled cardiac arrhythmia

               -  Symptomatic congestive heart failure (i.e., New York Heart Association class
                  II-IV)

               -  Unstable angina pectoris

               -  Clinically significant peripheral vascular disease

          -  No arterial thromboses within the past year, including any of the following:

               -  Transient ischemic attack

               -  Myocardial infarction

               -  Cerebrovascular event

               -  Unstable angina

               -  Angina requiring medical or surgical intervention

               -  Clinically significant peripheral artery disease

               -  Any other arterial thromboembolic event

          -  No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the
             lung

          -  No serious nonhealing wound, ulcer, or bone fracture

          -  No other active second malignancy except nonmelanoma skin cancer or cervical carcinoma
             in situ unless therapy has been completed and < 30% risk for relapse exists

          -  No active infection or known HIV infection

          -  No history of allergic reactions (≥ grade 3 or 4) to compounds of similar chemical or
             biologic composition to cyclophosphamide (i.e., alkylating agents)

          -  No history of noncompliance with medical regimens

          -  No known intolerance or hypersensitivity reaction to bevacizumab, imatinib mesylate,
             or cyclophosphamide

          -  No other significant medical illness, psychiatric illness, or social situation that,
             in the opinion of the investigator, would limit compliance with study requirements

          -  No inability to grant reliable informed consent

        PRIOR CONCURRENT THERAPY:

          -  No major surgical procedure within the past 28 days or anticipated major surgery
             during study treatment except for placement of a venous access device or surgery for a
             diagnostic study